Latest

After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆

Search Results

Found 4 results for "medicine pricing" across articles, medicines, trials, companies and the glossary

The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories

Regulatory Affairs

The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories

An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.

The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments

The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments

An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.

Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing

Regulatory Affairs

Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing

The Competition and Consumer Protection Commission (CCPC) has launched a comprehensive market study into Ireland's retail pharmacy sector, targeting opaque pricing practices and a lack of competition.

Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029

Regulatory Affairs

Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029

The Irish government signs major new Framework Agreements with MFI and IPHA, aiming to reduce patient wait times for innovative treatments to 180 days by 2029.